Close

Registration is free and only takes a moment. If you have already registered, please log in now.

Create Account
Forgot your password?
Log In
  • Links
  • Publisher Full Text
  • Authors
  • Rindi G
  • Caplin M
  • MESH
  • Antineoplastic Agents, Hormonal
  • Carcinoid Tumor
  • Female
  • Humans
  • Immunosuppressive Agents
  • Male
  • Malignant Carcinoid Syndrome
  • Octreotide
  • Sirolimus

Unbound MEDLINE

mTOR inhibitor therapy for patients with carcinoid.

Links

  • Publisher Full Text
  • Authors

    Rindi G, Caplin M

    Institution

    Institute of Pathology, Università Cattolica-Policlinico A. Gemelli, 00168 Rome, Italy. guido.rindi@rm.unicatt.it

    Source

    Lancet 378:9808 2011 Dec 10 pg 1978-80

    MeSH

    Antineoplastic Agents, Hormonal
    Carcinoid Tumor
    Female
    Humans
    Immunosuppressive Agents
    Male
    Malignant Carcinoid Syndrome
    Octreotide
    Sirolimus

    Pub Type(s)

    Comment
    Journal Article

    Language

    eng

    PubMed ID

    22119494

    Related Citations

    • Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
    • Primary hepatic carcinoid tumor with carcinoid syndrome and carcinoid heart disease: a case report of a patient on long-term follow-up.
    • Regression of sclerodermatous skin lesions in a patient with carcinoid syndrome treated by octreotide.
    • Long-standing malignant pancreatic carcinoid treated with octreotide.
    • Carcinoid tumours and the role of Sandostatin.
    • [Analogs of somatostatin and carcinoid tumors].
    • Comments on "Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients".
    • [Update on the anesthetic management of patients with malignant carcinoid syndrome].
    More
    unbound logo
    • Home »
    • Contact Us »
    • Help »
    • Privacy / Disclaimer »
    • Terms of Service »
    • Log In »
    • twitter
    • facebook
    © 2000–2013 Unbound Medicine, Inc. All rights reserved